EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.
Medscape News Europe

Source link : https://www.medscape.com/viewarticle/ema-backs-breast-cancer-serd-after-fda-no-vote-2026a1000gsm?src=rss

Author :

Publish date : 2026-05-22 14:17:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

EMA Backs Breast Cancer SERD After FDA No Vote

Prostate Cancer Drug Linked to Lower Risk of Cognitive Decline

Related Posts

Prostate Cancer Drug Linked to Lower Risk of Cognitive Decline

UK scientists developing new Ebola vaccine that could be ready in months

FRAX Predicts Surgery Benefit in Hyperparathyroidism

The Ebola Outbreak in Congo Went Unnoticed for Weeks. This Is What We Know.

Australia is battling its largest diphtheria outbreak in living memory

Robotic Wearable Helps Children With SMA Stand Independently

EMA Backs Breast Cancer SERD After FDA No Vote

Prostate Cancer Drug Linked to Lower Risk of Cognitive Decline

UK scientists developing new Ebola vaccine that could be ready in months

FRAX Predicts Surgery Benefit in Hyperparathyroidism

The Ebola Outbreak in Congo Went Unnoticed for Weeks. This Is What We Know.

Australia is battling its largest diphtheria outbreak in living memory

Robotic Wearable Helps Children With SMA Stand Independently

NICE Backs New Targeted Therapy for Advanced Cervical Cancer

Categories

Archives